Abstract:"Drug resistance is an unavoidable consequence of the use of drugs; however, the emergence of multi-drug resistance can be managed by accurate diagnosis and tailor-made regimens."Antimicrobial resistance (AMR), is one of the most paramount health perils that has emerged in the 21st century. The global increase in drug-resistant strains of various bacterial pathogens prompted the World Health Organization (WHO) to develop a priority list of AMR pathogens. Mycobacterium tuberculosis (Mtb), an acid-fast bacillus that causes tuberculosis (TB), merits being one of the highest priority pathogens on this list since drug-resistant TB (DR-TB) accounts for ∼29% of deaths attributable to AMR. In recent years, funded collaborative efforts of researchers from academia, not-for-profit virtual R&D organizations and industry have resulted in the continuous growth of the TB drug discovery and development pipeline. This has so far led to the accelerated regulatory approval of bedaquiline and delamanid for the treatment of DR-TB. However, despite the availability of drug regimes, the current cure rate for multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) treatment regimens is 50% and 30%, respectively. It is to be noted that these regimens are administered over a long duration and have a serious side effect profile. Coupled with poor patient adherence, this has led to further acquisition of drug resistance and treatment failure. There is therefore an urgent need to develop new TB drugs with novel mechanism of actions (MoAs) and associated regimens.This Account recapitulates drug resistance in TB, existing challenges in addressing DR-TB, new drugs and regimens in development, and potential ways to treat DR-TB. We highlight our research aimed at identifying novel small molecule leads and associated targets against TB toward contributing to the global TB drug discovery and development pipeline. Our work mainly involves screening of various small molecule chemical libraries in phenotypic whole-cell based assays to identify hits for medicinal chemistry optimization, with attendant deconvolution of the MoA. We discuss the identification of small molecule chemotypes active against Mtb and subsequent structure–activity relationships (SAR) and MoA deconvolution studies. This is followed by a discussion on a chemical series identified by whole-cell cross-screening against Mtb, for which MoA deconvolution studies revealed a pathway that explained the lack of in vivo efficacy in a mouse model of TB and reiterated the importance of selecting an appropriate growth medium during phenotypic screening. We also discuss our efforts on drug repositioning toward addressing DR-TB. In the concluding section, we preview some promising future directions and the challenges inherent in advancing the drug pipeline to address DR-TB.This article has not yet been cited by other publications.

Actionable mechanisms of drug tolerance and resistance in Mycobacterium tuberculosis

The past, present and future of tuberculosis treatment.

Mechanisms of drug action and resistance in Mycobacterium tuberculosis

Strategies to Combat Multi-Drug Resistance in Tuberculosis

The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

Metabolic Rewiring of Mycobacterium tuberculosis upon Drug Treatment and Antibiotics Resistance

Recent updates on drug resistance in Mycobacterium tuberculosis

Evolution of Drug-Resistant Mycobacterium tuberculosis Strains and Their Adaptation to the Human Lung Environment

Decoding drug resistance in Mycobacterium tuberculosis complex: genetic insights and future challenges

Mycobacterial biofilms: A therapeutic target against bacterial persistence and generation of antibiotic resistance

Multitargeting: An Alternative Approach to Tackle Multidrug Resistance in Tuberculosis

Host-directed therapy against tuberculosis: Concept and recent developments

Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis

Mycobacterium Tuberculosis Carrying a Rifampicin Drug Resistance Mutation Reprograms Macrophage Metabolism Through Cell Wall Lipid Changes

Mycobacterium Tuberculosis Functional Genetic Diversity, Altered Drug Sensitivity, and Precision Medicine.

Drug Resistance Tomycobacterium Tuberculosis: from the Traditional Chinese View to Modern Systems Biology

Emerging Drugs and Drug Targets Against Tuberculosis

Drug targets, current and future therapeutics for the treatment of multi drug resistant tuberculosis with their clinical applications: A critical review

Unlocking the enigma of phenotypic drug tolerance: Mechanisms and emerging therapeutic strategies

Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis

Mycobacterial response to an acidic environment: protective mechanisms